Various SCN1a alterations correspond with different levels of loss-of-function, and less frequently, gain-of-function mutations in the sodium channel, explaining the wide variability in DS severity and therapeutic response to antiseizure medications (29, 34). The gene discussed is SCN1A; the disease is Dravet syndrome.